
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Tactile Systems Technology Inc (TCMD)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TCMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $13.5
1 Year Target Price $13.5
1 | Strong Buy |
0 | Buy |
4 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 92.78% | Avg. Invested days 57 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 275.98M USD | Price to earnings Ratio 19.97 | 1Y Target Price 13.5 |
Price to earnings Ratio 19.97 | 1Y Target Price 13.5 | ||
Volume (30-day avg) 5 | Beta 0.96 | 52 Weeks Range 8.61 - 21.10 | Updated Date 08/15/2025 |
52 Weeks Range 8.61 - 21.10 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When Before Market | Estimate 0.17 | Actual 0.14 |
Profitability
Profit Margin 5.06% | Operating Margin (TTM) 5.18% |
Management Effectiveness
Return on Assets (TTM) 4.27% | Return on Equity (TTM) 7.64% |
Valuation
Trailing PE 19.97 | Forward PE 18.48 | Enterprise Value 222165755 | Price to Sales(TTM) 0.92 |
Enterprise Value 222165755 | Price to Sales(TTM) 0.92 | ||
Enterprise Value to Revenue 0.74 | Enterprise Value to EBITDA 7.57 | Shares Outstanding 22292100 | Shares Floating 19654315 |
Shares Outstanding 22292100 | Shares Floating 19654315 | ||
Percent Insiders 2.73 | Percent Institutions 101.71 |
Upturn AI SWOT
Tactile Systems Technology Inc

Company Overview
History and Background
Tactile Systems Technology Inc. was founded in 1993 and is headquartered in Minneapolis, Minnesota. The company focuses on developing and marketing medical devices for the treatment of chronic diseases.
Core Business Areas
- Lymphedema and Chronic Venous Insufficiency (CVI): Develops and markets pneumatic compression devices that treat lymphedema and CVI by increasing circulation in the affected area. These are the Flexitouch and ACTitouch Systems.
Leadership and Structure
The CEO is Daniel Reuvers. The company is structured with departments like Sales, Marketing, Research and Development, and Operations.
Top Products and Market Share
Key Offerings
- Flexitouch System: Pneumatic compression device for treating lymphedema and chronic venous insufficiency. Revenue from this product is a significant portion of the company's total revenue. Competitors include companies offering similar pneumatic compression devices, such as Bio Compression Systems, and Medi GmbH & Co. KG.
- Market Share: Cannot be accurately determined without access to proprietary market research data. It's a significant player but the overall market is fragmented. Some sources say they have over 50,000 users
- ACTitouch System: A smaller, more portable pneumatic compression device intended for home use for treating lymphedema and chronic venous insufficiency. This smaller device allows for better ease of use for consumers. Some competitors are compression socks, compression shirts etc.
- Market Share: Market share for this product is relatively smaller than Flexitouch System but has been growing. Cannot be accurately determined without access to proprietary market research data.
Market Dynamics
Industry Overview
The market for lymphedema and chronic venous insufficiency treatment devices is growing due to an aging population and increased awareness of these conditions.
Positioning
Tactile Systems Technology Inc. is a key player in the pneumatic compression device market. Their competitive advantage lies in their focused product portfolio and specialized technology.
Total Addressable Market (TAM)
The TAM for lymphedema treatment devices is estimated to be in the hundreds of millions of dollars. Tactile Systems Technology Inc. is well-positioned to capture a significant portion of this market. $4B by 2030, the market is fragmented with no one competitor dominating this specific niche.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio focused on lymphedema and CVI treatment.
- Established market presence and brand recognition.
- Strong relationships with healthcare providers and reimbursement specialists.
Weaknesses
- Reliance on reimbursement approvals for sales growth.
- Limited product diversification compared to larger medical device companies.
- Susceptible to changes in healthcare regulations.
Opportunities
- Expanding product offerings to address related conditions.
- Increasing market penetration through direct-to-consumer marketing.
- Acquiring complementary technologies or businesses.
Threats
- Increased competition from established medical device companies.
- Changes in reimbursement policies negatively impacting product pricing.
- Product liability claims.
Competitors and Market Share
Key Competitors
- Bio Compression Systems, Inc
- Medi GmbH & Co. KG
- Lympha Press (US stock is unclear, commonly from Israel, LPEM.TA)
- SIGVARIS
Competitive Landscape
Tactile Systems Technology Inc. competes with a mix of specialized medical device companies and larger, more diversified players. Their strengths lie in their specialized focus and established relationships with healthcare providers, while weaknesses are their dependency on reimbursement approval and a lack of diversification.
Growth Trajectory and Initiatives
Historical Growth: Analysis requires access to historical financial data from official data sources. Unable to provide real-time financial data.
Future Projections: Analysis requires access to up-to-date analyst estimates from official data sources. Unable to provide real-time financial data.
Recent Initiatives: Requires knowledge of their latest actions for example acquisitions, partnerships or mergers. Unable to provide without real-time source data.
Summary
Tactile Systems Technology Inc. focuses on lymphedema and CVI treatment using pneumatic compression devices. It has established relationships with healthcare providers. The company needs to expand its product offerings. Reimbursement approvals and competition are the major concerns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and company specifics may change over time. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tactile Systems Technology Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2016-07-28 | CEO, President & Director Ms. Sheri Louise Dodd | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1037 | Website https://tactilemedical.com |
Full time employees 1037 | Website https://tactilemedical.com |
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.